Document is current
Any future updates will be listed below
-
Authors
Prasad, Deepika
Baldelli, Elisa
Blais, Edik M.
Davis, Justin
El Gazzah, Emna
Mueller, Claudius
Gomeiz, Alison
Ibrahim, Aisha
Newrekar, Avani Vinayak
Corgiat, Brian A.
Dunetz, Rick
Petricoin III, Emanuel F.
Wei, Qi
Pierobon, Mariaelena http://orcid.org/0000-0003-2084-1029
-
Funding
Funding for this research was provided by:
Side Out Foundation
- License Information
-
More Information
Article History
Received: 6 May 2024
Revised: 4 September 2024
Accepted: 6 September 2024
First Online: 25 September 2024
Competing interests
: The authors are inventors of US Government and University-assigned patents and patent applications covering aspects of the technologies. As inventors, they are entitled to receive royalties as provided by US Law and George Mason University policy. MP and EFP receive royalties from Theralink Technologies, Inc. MP and EFP are consultants to and/or shareholders of Theralink Technologies, Inc; EFP is a shareholder and consultant of Perthera, Inc.
: The retrospective cohort of 176 metastatic breast cancer patients was analysed from Perthera’s platform, where patients are registered on an IRB-approved observational protocol (WCG IRB Protocol ID: PCT-01-012). Patients entered the study voluntarily, and each participant provided informed consent. The study was conducted following the Declaration of Helsinki guidelines.
